SCHEDULE: Harel Insurance Boosts Teva Stake to 6.3%
Beneficial Ownership Disclosure
Harel Insurance Investments & Financial Services Ltd. has reported a 6.3% beneficial ownership stake in Teva Pharmaceutical Industries Ltd. as of December 31, 2025.
Summary
- Harel Insurance Investments & Financial Services Ltd. reported beneficial ownership of 72,325,555 Ordinary Shares of Teva Pharmaceutical Industries Ltd.
- This represents 6.3% of Teva's outstanding Ordinary Shares.
- The ownership is based on 1,149,812,898 Ordinary Shares issued and outstanding as of December 31, 2025, as reported by Teva in its Annual Report on Form 10-K filed on February 3, 2026.
- The shares are primarily held for members of the public through provident funds, mutual funds, pension funds, insurance policies, and exchange-traded funds (70,039,163 shares).
- A portion is held by third-party client accounts managed by a subsidiary (1,090,246 shares) and for Harel's own account (1,196,146 shares).
- Harel Insurance has shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure of beneficial ownership, providing transparency without inherently positive or negative operational news.
Positives
- A significant institutional investor, Harel Insurance, maintains a substantial 6.3% beneficial ownership in Teva Pharmaceutical Industries Ltd., providing transparency regarding its continued investment.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional filings like this provide transparency into significant ownership stakes, which can influence market perception of a company's stability and investor confidence within the pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can contribute to market confidence and liquidity.
- Teva Management: Awareness of a large institutional holder's position, which may influence corporate engagement strategies.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires filing of this statement and the date for outstanding shares calculation. |
| 02/03/2026 | Date Teva Pharmaceutical Industries Ltd. filed its Annual Report on Form 10-K, reporting outstanding shares. |
| 02/09/2026 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Teva Pharmaceutical, Harel Insurance, Schedule 13G, beneficial ownership, institutional investment, ordinary shares, M8769Q102
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.